139 related articles for article (PubMed ID: 15496971)
21. Efficacy of alemtuzumab in cutaneous chronic lymphocytic leukaemia involving facial skin.
Grey M
Br J Haematol; 2008 Jul; 142(1):1. PubMed ID: 18477054
[No Abstract] [Full Text] [Related]
22. Campath in haemolytic anaemia and chronic lymphatic leukaemia: an unsuccessful case.
Ames PR; Aw D; Rainey MG
Leukemia; 2007 Nov; 21(11):2380-1. PubMed ID: 17568817
[No Abstract] [Full Text] [Related]
23. Advances in the use of alemtuzumab in CLL.
Stilgenbauer S
Clin Adv Hematol Oncol; 2008 Jan; 6(1):23-4. PubMed ID: 18322437
[No Abstract] [Full Text] [Related]
24. Treatment of severe autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab.
Royer B; Vaida I; Etienne A; Garidi R; Damaj G; Marolleau JP
Leukemia; 2007 Aug; 21(8):1841-2; author reply 1842-3. PubMed ID: 17460703
[No Abstract] [Full Text] [Related]
25. Hillmen trial of alemtuzumab in first-line chronic lymphocytic leukemia still provides valuable information.
Sirard C; Trehu EG
J Clin Oncol; 2008 May; 26(14):2411-2; author reply 2412-3. PubMed ID: 18467736
[No Abstract] [Full Text] [Related]
26. Berlex Laboratories to market new treatment for B-CLL.
Expert Rev Anticancer Ther; 2001 Jun; 1(1):3. PubMed ID: 12113127
[No Abstract] [Full Text] [Related]
27. Alemtuzumab.
Am J Health Syst Pharm; 2001 Dec; 58(24):2372-3. PubMed ID: 11794950
[No Abstract] [Full Text] [Related]
28. Tuberculosis due to Mycobacterium bovis after alemtuzumab administration.
Abad S; Gyan E; Moachon L; Bouscary D; Sicard D; Dreyfus F; Blanche P
Clin Infect Dis; 2003 Jul; 37(2):e27-8. PubMed ID: 12856232
[TBL] [Abstract][Full Text] [Related]
29. Progress with alemtuzumab in chronic lymphocytic leukemia: Update from the 2003 meeting of the american society of hematology.
Lee D
Clin Lymphoma; 2004 Mar; 4(4):217-9. PubMed ID: 15072612
[No Abstract] [Full Text] [Related]
30. Alemtuzumab, the first monoclonal antibody (MAb) directed against CD52.
Keating M; Hallek M
Med Oncol; 2002; 19 Suppl():S1-2. PubMed ID: 12180486
[No Abstract] [Full Text] [Related]
31. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.
Rai KR; Freter CE; Mercier RJ; Cooper MR; Mitchell BS; Stadtmauer EA; Santábarbara P; Wacker B; Brettman L
J Clin Oncol; 2002 Sep; 20(18):3891-7. PubMed ID: 12228210
[TBL] [Abstract][Full Text] [Related]
32. Treatment with campath-1H for relapsed chronic lymphocytic leukemia after allogeneic peripheral blood stem cell transplantation does not abrogate the development of chronic GVHD.
Wolff D; Steiner B; Stilgenbauer S; Kahl C; Leithäuser M; Junghanss C; Wilhelm S; Kleine HD; Zimmermann R; Hartung G; Casper J; Freund M
Eur J Haematol; 2004 Feb; 72(2):145-8. PubMed ID: 14962253
[TBL] [Abstract][Full Text] [Related]
33. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
Robak T
Transfus Apher Sci; 2005 Feb; 32(1):33-44. PubMed ID: 15737872
[TBL] [Abstract][Full Text] [Related]
34. Alemtuzumab in chronic lymphocytic leukemia.
James DF; Kipps TJ
Future Oncol; 2007 Feb; 3(1):29-42. PubMed ID: 17280499
[TBL] [Abstract][Full Text] [Related]
35. [Campath-1H--a monoclonal antibody for treatment of non-Hodgkin's and chronic lymphatic leukemia].
de Nully Brown P; Hansen MM; Nissen NI
Ugeskr Laeger; 1997 Jul; 159(28):4389-93. PubMed ID: 9235735
[TBL] [Abstract][Full Text] [Related]
36. A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with hemotherapy-refractory chronic lymphocytic leukemia.
Cortelezzi A; Pasquini MC; Sarina B; Bertani G; Grifoni F; Colombi M; Lambertenghi Deliliers G
Haematologica; 2005 Mar; 90(3):410-2. PubMed ID: 15749678
[TBL] [Abstract][Full Text] [Related]
37. A review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation.
Reiff A
Hematology; 2005 Apr; 10(2):79-93. PubMed ID: 16019453
[TBL] [Abstract][Full Text] [Related]
38. Cutaneous cryptococcosis with alemtuzumab in a patient treated for chronic lymphocytic leukaemia.
Dilhuydy MS; Jouary T; Demeaux H; Ravaud A
Br J Haematol; 2007 Jun; 137(6):490. PubMed ID: 17425643
[No Abstract] [Full Text] [Related]
39. Update on prophylaxis and therapy of infection in patients with chronic lymphocytic leukemia.
Morrison VA
Expert Rev Anticancer Ther; 2001 Jun; 1(1):84-90. PubMed ID: 12113137
[TBL] [Abstract][Full Text] [Related]
40. Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria.
Fiegl M; Falkner A; Hopfinger G; Brugger S; Zabernigg A; Bauer F; Haslbauer F; Demirtas D; Grossschmidt P; Tatzreiter G; Gastl G; Greil R;
Cancer; 2006 Nov; 107(10):2408-16. PubMed ID: 17054106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]